PURPOSE: This article updates response duration and survival data for patients with metastatic renal cell carcinoma receiving high-dose recombinant interleukin-2 (rIL-2). PATIENTS AND METHODS: Two hundred fifty-five assessable renal cell carcinoma patients were entered into seven phase II clinical trials. They were administered 600,000 or 720,000 IU/kg rIL-2 by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximal support. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. All data have been updated as of June 1996 with report forms completed by the clinical investigators. RESULTS: Objective overall responses have now been achieved in 37 of 255 patients (15%) with 17 complete (7%) and 20 partial (8%) responses. Median response duration for all objective responders is 54 months with a range of 3 to 107+ months. Median response duration for all complete responses has not been reached, with a range of 7 to 107+ months. Median response duration for all partial responses is 20 months, with a range of 3 to 97+ months. Median survival for all 255 patients was 16.3 months, and 10% to 20% of patients were estimated to be alive 5 to 10 years following treatment. CONCLUSION: Treatment with high-dose rIL-2 is extremely effective for a subset of patients with metastatic renal cell carcinoma.
PURPOSE: This article updates response duration and survival data for patients with metastatic renal cell carcinoma receiving high-dose recombinant interleukin-2 (rIL-2). PATIENTS AND METHODS: Two hundred fifty-five assessable renal cell carcinomapatients were entered into seven phase II clinical trials. They were administered 600,000 or 720,000 IU/kg rIL-2 by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximal support. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. All data have been updated as of June 1996 with report forms completed by the clinical investigators. RESULTS: Objective overall responses have now been achieved in 37 of 255 patients (15%) with 17 complete (7%) and 20 partial (8%) responses. Median response duration for all objective responders is 54 months with a range of 3 to 107+ months. Median response duration for all complete responses has not been reached, with a range of 7 to 107+ months. Median response duration for all partial responses is 20 months, with a range of 3 to 97+ months. Median survival for all 255 patients was 16.3 months, and 10% to 20% of patients were estimated to be alive 5 to 10 years following treatment. CONCLUSION: Treatment with high-dose rIL-2 is extremely effective for a subset of patients with metastatic renal cell carcinoma.
Authors: Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels Journal: World J Urol Date: 2005-04-02 Impact factor: 4.226
Authors: Che-Kai Tsao; Bobby Liaw; Catherine He; Matthew D Galsky; John Sfakianos; William K Oh Journal: Ther Adv Med Oncol Date: 2017-02-14 Impact factor: 8.168
Authors: James C Yang; Richard M Sherry; Seth M Steinberg; Suzanne L Topalian; Douglas J Schwartzentruber; Patrick Hwu; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Donald E White; David J Liewehr; Maria J Merino; Steven A Rosenberg Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Peter J Van Veldhuizen; Michael Hussey; Primo N Lara; Philip C Mack; Regina Gandour-Edwards; Joseph I Clark; Marianne K Lange; David E Crawford Journal: Am J Clin Oncol Date: 2009-10 Impact factor: 2.339